304 related articles for article (PubMed ID: 25468897)
21. In Vitro Assays to Assess Exon Skipping in Duchenne Muscular Dystrophy.
Boisguerin P; O'Donovan L; Gait MJ; Lebleu B
Methods Mol Biol; 2015; 1324():317-29. PubMed ID: 26202278
[TBL] [Abstract][Full Text] [Related]
22. Identification of a Peptide for Systemic Brain Delivery of a Morpholino Oligonucleotide in Mouse Models of Spinal Muscular Atrophy.
Shabanpoor F; Hammond SM; Abendroth F; Hazell G; Wood MJA; Gait MJ
Nucleic Acid Ther; 2017 Jun; 27(3):130-143. PubMed ID: 28118087
[TBL] [Abstract][Full Text] [Related]
23. Dosing regimen has a significant impact on the efficiency of morpholino oligomer-induced exon skipping in mdx mice.
Malerba A; Thorogood FC; Dickson G; Graham IR
Hum Gene Ther; 2009 Sep; 20(9):955-65. PubMed ID: 19469709
[TBL] [Abstract][Full Text] [Related]
24. Designing Effective Antisense Oligonucleotides for Exon Skipping.
Shimo T; Maruyama R; Yokota T
Methods Mol Biol; 2018; 1687():143-155. PubMed ID: 29067661
[TBL] [Abstract][Full Text] [Related]
25. In silico screening based on predictive algorithms as a design tool for exon skipping oligonucleotides in Duchenne muscular dystrophy.
Echigoya Y; Mouly V; Garcia L; Yokota T; Duddy W
PLoS One; 2015; 10(3):e0120058. PubMed ID: 25816009
[TBL] [Abstract][Full Text] [Related]
26. Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy.
Echigoya Y; Nakamura A; Nagata T; Urasawa N; Lim KRQ; Trieu N; Panesar D; Kuraoka M; Moulton HM; Saito T; Aoki Y; Iversen P; Sazani P; Kole R; Maruyama R; Partridge T; Takeda S; Yokota T
Proc Natl Acad Sci U S A; 2017 Apr; 114(16):4213-4218. PubMed ID: 28373570
[TBL] [Abstract][Full Text] [Related]
27. Design and application of bispecific splice-switching oligonucleotides.
Bestas B; McClorey G; Tedebark U; Moreno PM; Roberts TC; Hammond SM; Smith CI; Wood MJ; Andaloussi SE
Nucleic Acid Ther; 2014 Feb; 24(1):13-24. PubMed ID: 24506779
[TBL] [Abstract][Full Text] [Related]
28. Parallel synthesis of cell-penetrating peptide conjugates of PMO toward exon skipping enhancement in Duchenne muscular dystrophy.
O'Donovan L; Okamoto I; Arzumanov AA; Williams DL; Deuss P; Gait MJ
Nucleic Acid Ther; 2015 Feb; 25(1):1-10. PubMed ID: 25412073
[TBL] [Abstract][Full Text] [Related]
29. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.
Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T
Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998
[TBL] [Abstract][Full Text] [Related]
30. Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD.
McClorey G; Moulton HM; Iversen PL; Fletcher S; Wilton SD
Gene Ther; 2006 Oct; 13(19):1373-81. PubMed ID: 16724091
[TBL] [Abstract][Full Text] [Related]
31. Shorter Phosphorodiamidate Morpholino Splice-Switching Oligonucleotides May Increase Exon-Skipping Efficacy in DMD.
Akpulat U; Wang H; Becker K; Contreras A; Partridge TA; Novak JS; Cirak S
Mol Ther Nucleic Acids; 2018 Dec; 13():534-542. PubMed ID: 30396145
[TBL] [Abstract][Full Text] [Related]
32. Development and Application of an Ultrasensitive Hybridization-Based ELISA Method for the Determination of Peptide-Conjugated Phosphorodiamidate Morpholino Oligonucleotides.
Burki U; Keane J; Blain A; O'Donovan L; Gait MJ; Laval SH; Straub V
Nucleic Acid Ther; 2015 Oct; 25(5):275-84. PubMed ID: 26176274
[TBL] [Abstract][Full Text] [Related]
33. In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping.
Heemskerk HA; de Winter CL; de Kimpe SJ; van Kuik-Romeijn P; Heuvelmans N; Platenburg GJ; van Ommen GJ; van Deutekom JC; Aartsma-Rus A
J Gene Med; 2009 Mar; 11(3):257-66. PubMed ID: 19140108
[TBL] [Abstract][Full Text] [Related]
34. Enhancing Antisense Oligonucleotide-Based Therapeutic Delivery with DG9, a Versatile Cell-Penetrating Peptide.
Haque US; Yokota T
Cells; 2023 Oct; 12(19):. PubMed ID: 37830609
[TBL] [Abstract][Full Text] [Related]
35. Improved cell-penetrating peptide-PNA conjugates for splicing redirection in HeLa cells and exon skipping in mdx mouse muscle.
Ivanova GD; Arzumanov A; Abes R; Yin H; Wood MJ; Lebleu B; Gait MJ
Nucleic Acids Res; 2008 Nov; 36(20):6418-28. PubMed ID: 18842625
[TBL] [Abstract][Full Text] [Related]
36. Hexose enhances oligonucleotide delivery and exon skipping in dystrophin-deficient mdx mice.
Han G; Gu B; Cao L; Gao X; Wang Q; Seow Y; Zhang N; Wood MJ; Yin H
Nat Commun; 2016 Mar; 7():10981. PubMed ID: 26964641
[TBL] [Abstract][Full Text] [Related]
37. Morpholino-induced exon skipping stimulates cell-mediated and humoral responses to dystrophin in mdx mice.
Vila MC; Novak JS; Benny Klimek M; Li N; Morales M; Fritz AG; Edwards K; Boehler JF; Hogarth MW; Kinder TB; Zhang A; Mazala D; Fiorillo AA; Douglas B; Chen YW; van den Anker J; Lu QL; Hathout Y; Hoffman EP; Partridge TA; Nagaraju K
J Pathol; 2019 Jul; 248(3):339-351. PubMed ID: 30883742
[TBL] [Abstract][Full Text] [Related]
38. Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing.
Hanson B; Wood MJA; Roberts TC
RNA Biol; 2021 Jul; 18(7):1048-1062. PubMed ID: 33472516
[TBL] [Abstract][Full Text] [Related]
39. CPP-directed oligonucleotide exon skipping in animal models of Duchenne muscular dystrophy.
Yin H; Moulton H; Betts C; Wood M
Methods Mol Biol; 2011; 683():321-38. PubMed ID: 21053140
[TBL] [Abstract][Full Text] [Related]
40. A novel human muscle cell model of Duchenne muscular dystrophy created by CRISPR/Cas9 and evaluation of antisense-mediated exon skipping.
Shimo T; Hosoki K; Nakatsuji Y; Yokota T; Obika S
J Hum Genet; 2018 Mar; 63(3):365-375. PubMed ID: 29339778
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
